- Home
- EDTK vs APLT Comparison
EDTK vs APLT Comparison
Compare EDTK & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDTK | APLT |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.3M | 14.4M |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | EDTK | APLT |
|---|---|---|
| Price | $1.01 | $0.11 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $1.25 |
| AVG Volume (30 Days) | 23.3K | ★ 11.8M |
| Earning Date | 03-09-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $893,690.00 | ★ $1,000,000.00 |
| Revenue This Year | N/A | $124.18 |
| Revenue Next Year | N/A | $25.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.80 | $0.09 |
| 52 Week High | $1.18 | $1.50 |
Technical Indicators
Market Signals| Indicator | EDTK | APLT |
|---|---|---|
| Relative Strength Index (RSI) | 64.07 | 31.12 |
| Support Level | $0.91 | $0.10 |
| Resistance Level | $1.00 | $0.11 |
| Average True Range (ATR) | 0.05 | 0.01 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 94.87 | 62.92 |
Price Performance
Historical ComparisonAbout EDTK Skillful Craftsman Education Technology Limited
Skillful Craftsman Education Technology Ltd provides online education and technology services in China. The services comprises of two aspects - Online vocational training and Virtual simulation experimental training. It covers a wide range of subjects, including mechanics, electronics, auto repair and construction. Majority of its revenues are generated from the People's Republic of China.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.